Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Centessa Pharmaceuticals ( (CNTA) ) has shared an announcement.
Centessa Pharmaceuticals announced updates on its OX2R agonist pipeline, including ORX750, ORX142, and ORX489, with significant clinical milestones anticipated in 2025. The company aims to position itself as a leader in the emerging category of OX2R agonist therapeutics, bolstered by a strong balance sheet and an estimated cash runway into mid-2027.
More about Centessa Pharmaceuticals
Centessa Pharmaceuticals operates in the pharmaceutical industry, focusing on discovering and developing transformative medicines. The company’s primary products include a pipeline of orexin receptor 2 (OX2R) agonists, with a market focus on treating sleep-wake, neurological, neurodegenerative, and psychiatric disorders.
YTD Price Performance: -1.03%
Average Trading Volume: 529,748
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $2.2B
For an in-depth examination of CNTA stock, go to TipRanks’ Stock Analysis page.
